Elanco Animal Health (NYSE:ELAN) Releases Q2 2023 Earnings Guidance

Elanco Animal Health (NYSE:ELAN – Get Rating) issued an update on its second quarter 2023 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 0-$0.05 for the period, compared to the consensus estimate of $0.19. The company issued revenue guidance of $1.00 billion-$1.05 billion, compared to the consensus revenue estimate […]

Related Keywords

R David Hoover ,Piper Sandler ,Jeffreyn Simmons ,Barclays ,Elanco Animal Health Inc ,News Ratings For Elanco Animal Health Daily ,Morgan Stanley ,Elanco Animal Health ,Guggenheim Capital ,Toroso Investments ,Elanco Animal Health Trading Down ,Elanco Animal Health Company Profile ,Macquarie Group Ltd ,Food Animal Future Protein Health ,Pearl River Capital ,Securities Exchange Commission ,Get Rating ,Animal Health ,Animal Health Trading Down ,Directorr David Hoover ,Exchange Commission ,River Capital ,Macquarie Group ,Companion Animal Disease Prevention ,Companion Animal Therapeutics ,Food Animal Future Protein ,Food Animal Ruminants ,Elanco Animal Health Daily ,